Merck Sharp + Dohme Corp.

Sean P Ahearn

Alexey A Rivkin

Christopher J Dinsmore

David James Witter

Joon Jung

Matthew Christopher

Stephanie M Chichetti

Hua Zhou

Philip Jones

Benito Munoz

Joey Lee Methot

David Joseph Guerin

Mark E Scott

John W Butcher

Christian Fischer

Qinglin Pu

Brandon D Cash

Rachel Nicola MacCoss

Chaomin Li

June J Kim

Hyun Chong Woo

Adam J Schell

William Colby Brown

Sam Kattar

John T Hendrix

Andrew Rosenau

Raksha Archarya

John Hendrix

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Azaindoles as Janus kinase inhibitors

The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.

Pyrrolopyrimidines as janus kinase inhibitors

The invention encompasses pyrimidine derivatives as gamma secretase modulators, useful for treating diseases associated with the deposition of beta-amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases. Pharmaceutical compositions and methods of use are included.

Pyrimidine derivatives for treatment of alzheimer's disease

According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of A&#x3b2;42 and hence are useful in treatment of Alzheimer's disease and related conditions. 

Triazole derivatives for treatment of Alzheimer's disease

Growing community of inventors

Somerville, MA, United States of America

Sean P Ahearn